VLP-antigen conjugates and their uses as vaccines

Details VLP-antigen conjugates and their uses as vaccines VLP-antigen conjugates and their uses as vaccines

2011-06-14

2011-06-14

Chen, Stacy B. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S235100

Reexamination Certificate

active

07959928

ABSTRACT:
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.

REFERENCES:
patent: 4950599 (1990-08-01), Bertling
patent: 5534257 (1996-07-01), Mastico et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 6159728 (2000-12-01), Stockley et al.
patent: 6251678 (2001-06-01), Volkin et al.
patent: 6932971 (2005-08-01), Bachmann et al.
patent: 6964769 (2005-11-01), Sebbel et al.
patent: 7094409 (2006-08-01), Bachmann et al.
patent: 7115266 (2006-10-01), Bachmann
patent: 7128911 (2006-10-01), Bachmann et al.
patent: 7138252 (2006-11-01), Bachmann et al.
patent: 7264810 (2007-09-01), Renner et al.
patent: 7279165 (2007-10-01), Bachmann et al.
patent: 7320793 (2008-01-01), Renner et al.
patent: 2003/0091593 (2003-05-01), Bachmann et al.
patent: 2003/0099668 (2003-05-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2004/0005338 (2004-01-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2004/0136962 (2004-07-01), Renner et al.
patent: 2005/0191317 (2005-09-01), Bachmann et al.
patent: 2006/0088550 (2006-04-01), Bachmann et al.
patent: 2006/0204475 (2006-09-01), Bachmann et al.
patent: 2006/0210588 (2006-09-01), Bachmann et al.
patent: 2006/0251623 (2006-11-01), Bachmann et al.
patent: 2006/0251677 (2006-11-01), Bachmann et al.
patent: 2007/0184068 (2007-08-01), Renner et al.
patent: 2007/0248617 (2007-10-01), Bachmann et al.
patent: 0 648 272 (1997-10-01), None
patent: 0 572 433 (2001-05-01), None
patent: 0 591 369 (2001-09-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 03/024480 (2003-03-01), None
patent: WO 03/024481 (2003-03-01), None
patent: WO 04/000351 (2003-12-01), None
patent: WO 2004/009124 (2004-01-01), None
patent: WO 2004/084939 (2004-10-01), None
patent: WO 2004/084940 (2004-10-01), None
patent: WO 2004/085635 (2004-10-01), None
patent: WO 2005/004907 (2005-01-01), None
patent: WO 2005/048918 (2005-06-01), None
patent: WO 2005/068639 (2005-07-01), None
patent: WO 2005/108425 (2005-11-01), None
patent: WO 2005/117963 (2005-12-01), None
patent: WO 2006/027300 (2006-03-01), None
patent: WO 2006/032674 (2006-03-01), None
patent: WO 2007/144150 (2007-12-01), None
Abreu, M.T. and Arditi, M., “Innate Immunity and Toll-like Receptors: Clinical Implications of Basic Science Research,”J Pediatr. 144:421-429, Elsevier Science (Apr. 2004).
Bachmann, M.F. and Zinkernagel, R.M., “The Influence of Virus Structure on Antibody Responses and Virus Serotype Formation,”Immunol. Today 17:553-558, Elsevier Science (1996).
Bancroft, J.B., et al., “The Self-Assembly of a Nucleic-Acid Free Pseudo-Top Component for a Small Spherical Virus,”Virology 36:146-149, Academic Press (1968).
Bancroft, J.B., et al., “The Effects of Various Polyanions on Shell Formation of Some Spherical Viruses,”Virology 39:924-930, Academic Press (1968).
Beckett, D., et al., “Roles of Operator and Non-Operator RNA Sequences in Bacteriophage R17 Capsid Assembly,”J. Mol. Biol. 204:939-947, Academic Press (1988).
Chackerian, B., et al., “Induction of Autoantibodies to Mouse CCR5 with Recombinant Papillomavirus Particles,”Proc. Natl. Acad. Sci. USA 96:2373-2378, National Academy of Sciences (1999).
Diebold, S., et al., “Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA,”Science 303:1529-1531, American Association for the Advancement of Science (Mar. 2004).
Fehr, T., et al., “T Cell-Independent Type I Antibody Response Against B cell Epitopes Expressed Repetitively on Recombinant Virus Particles,”Proc. Natl. Acad. Sci. USA 95:9477-9481, National Academy of Sciences (1998).
Heal, K.G., et al., “Expression and Immunogenicity of a Liver Stage Malaria Epitope Presented as a Foreign Peptide on the Surface of RNA-Free MS2 Bacteriophage Capsids,”Vaccine 18:251-258, Elsevier Science (2000).
Heil, F., et al., “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8,”Science 303:1526-1529, American Association for the Advancement of Science (Mar. 2004).
Hohn, T., “The Assembly of Protein Particles of the RNA Bacteriophage fr in Absence of RNA,”Biochem. Biophys. Res. Commun. 36:7-17, Elsevier Science (1969).
Hohn, T., “Role of RNA in the Assembly Process of Bacteriophage fr,”J. Mol. Biol. 43:191-200, Elsevier Science (1969).
Kopp, E. and Medzhitov, R., “Recognition of Microbial Infection by Toll-like Receptors,”Curr. Opin. Immunol. 15:396-401, Elsevier Science (2003).
Kozlovska, T., et al., “RNA Phage Qβ Coat Protein as a Carrier for Foreign Epitopes,”Intervirology 39:9-15, S. Karger AG Basel (1996).
Mastico, R.A., et al., “Multiple Presentation of Foreign Peptides on the Surface of an RNA-Free Spherical Bacteriophage Capsid,”J. Gen. Virol. 74:541-548, The Society for General Microbiology (1993).
Rohrmann, G.F. and Krueger, R.G., “The Self-Assembly of RNA Free Protein Subunits from Bacteriophage MS-2,”Biochem. Biophys. Res. Commun. 38:406-413, Elsevier Science (1970).
Schwarz, K., et al., “Role of Toll-like Receptors in Costimulating Cytotoxic T cell Responses,”Eur. J. Immunol. 33:1465-1470, Wiley-VCH Verlag GmbH (2003).
Storni, T., et al., “Nonmethylated CG Motifs Packaged into Virus-like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects,”J. Immunol. 172:1777-1785, American Association of Immunologists (Feb. 2004).
Vasiljeva, I., et al., “Mosaic Qβ Coats as a New Presentation Model,”FEBS Lett. 431:7-11, Federation of European Biochemical Societies (1998).
Yang, T., et al., “Alternative Splicing of the Human Cholesteryl Ester Transfer Protein Gene in Transgenic Mice. Exon Exclusion Modulates Gene Expression in Response to Dietary or Developmental Change,”J. Biol. Chem. 271:12603-2609, The American Society for Biochemistry and Molecular Biology (1996).
Yang, Y., et al., “Persistent Toll-like Receptor Signals are Required for Reversal of Regulatory T Cell-Mediated CD8 Tolerance,”Nat. Immunol. 5:508-515, Nature Publishing Group (Apr. 2004).
Zhang, D., et al., “A Toll-like Receptor that Prevents Infection by Uropathogenic Bacteria,”Science 303:1522-1526, American Association for the Advancement of Science (Mar. 2004).

Affiliated with

Also associated with

Rating

VLP-antigen conjugates and their uses as vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with VLP-antigen conjugates and their uses as vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VLP-antigen conjugates and their uses as vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2666507